Cargando…

Significance of Metformin Use in Diabetic Kidney Disease

Metformin is a glucose-lowering agent that is used as a first-line therapy for type 2 diabetes (T2D). Based on its various pharmacologic actions, the renoprotective effects of metformin have been extensively studied. A series of experimental studies demonstrated that metformin attenuates diabetic ki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawanami, Daiji, Takashi, Yuichi, Tanabe, Makito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352798/ https://www.ncbi.nlm.nih.gov/pubmed/32545901 http://dx.doi.org/10.3390/ijms21124239

Ejemplares similares

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

The Role of Bone-Derived Hormones in Glucose Metabolism, Diabetic Kidney Disease, and Cardiovascular Disorders
por: Takashi, Yuichi, et al.
Publicado: (2022)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
por: Kawanami, Daiji, et al.
Publicado: (2020)

Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth
por: Tsutsumi, Yoko, et al.
Publicado: (2015)

Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
por: Matoba, Keiichiro, et al.
Publicado: (2019)

Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet
por: Horikawa, Tsuyoshi, et al.
Publicado: (2020)

ROCK Inhibition May Stop Diabetic Kidney Disease
por: Matoba, Keiichiro, et al.
Publicado: (2020)

Fibroblast growth factor 23 and kidney function in patients with type 1 diabetes
por: Takashi, Yuichi, et al.
Publicado: (2022)

Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives
por: Yanase, Tashihiko, et al.
Publicado: (2017)

Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
por: Kawanami, Daiji, et al.
Publicado: (2016)

Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression
por: Shigeoka, Toru, et al.
Publicado: (2020)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

A simplified prediction model for end-stage kidney disease in patients with diabetes
por: Inoguchi, Toyoshi, et al.
Publicado: (2022)

Prescription of oral hypoglycemic agents for patients with type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database
por: Tanabe, Makito, et al.
Publicado: (2016)

GLP-1 Receptor Agonist Exendin-4 Attenuates NR4A Orphan Nuclear Receptor NOR1 Expression in Vascular Smooth Muscle Cells
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

Metformin Protects against Podocyte Injury in Diabetic Kidney Disease
por: Lehtonen, Sanna
Publicado: (2020)

Lactic Acidosis Associated with Metformin in Patients with Diabetic Kidney Disease
por: Rahman, Fatkhu, et al.
Publicado: (2022)

Metformin improves diabetic kidney disease
por: Beladi Mousavi, Seyed Seifollah, et al.
Publicado: (2012)

Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
por: Terawaki, Yuichi, et al.
Publicado: (2014)

Metformin and Diabetic Kidney Disease: A Mini-Review on Recent Findings
por: Nasri, Hamid, et al.
Publicado: (2014)

Insight into the Molecular Mechanism of Diabetic Kidney Disease and the Role of Metformin in Its Pathogenesis
por: Kleibert, Marcin, et al.
Publicado: (2023)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
por: Kawanami, Daiji, et al.
Publicado: (2017)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
por: Takashi, Yuichi, et al.
Publicado: (2022)

Metformin: the updated protective property in kidney disease
por: Pan, Qingjun, et al.
Publicado: (2020)

Association between resistin and fibroblast growth factor 23 in patients with type 2 diabetes mellitus
por: Nakashima, Akio, et al.
Publicado: (2018)

Changes in metformin use in chronic kidney disease
por: Imam, Talha H.
Publicado: (2017)

Pharmacokinetics of metformin in patients with chronic kidney disease stage 4 and metformin‐naïve type 2 diabetes
por: Dissanayake, Ajith M., et al.
Publicado: (2018)

Extending Metformin Use in Diabetic Kidney Disease: A Pharmacokinetic Study in Stage 4 Diabetic Nephropathy
por: Dissanayake, Ajith Munasinghe, et al.
Publicado: (2017)

Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
por: Hur, Kyu Yeon, et al.
Publicado: (2020)

Gallic acid improves the metformin effects on diabetic kidney disease in mice
por: Hong, Yan, et al.
Publicado: (2023)

Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span
por: Takashi, Yuichi, et al.
Publicado: (2021)

Metformin in Gestational Diabetes Mellitus: To Use or Not to Use, That Is the Question
por: Tocci, Vera, et al.
Publicado: (2023)

The Effect of Metformin in Diabetic and Non-Diabetic Rats with Experimentally-Induced Chronic Kidney Disease
por: Za’abi, Mohammed Al, et al.
Publicado: (2021)

Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database
por: Tanabe, Makito, et al.
Publicado: (2015)

Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease
por: Bae, Jaehyun, et al.
Publicado: (2023)

Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
por: Hostalek, Ulrike, et al.
Publicado: (2015)

Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect
por: Corremans, Raphaëlle, et al.
Publicado: (2023)

Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease
por: Hsu, Wei-Hao, et al.
Publicado: (2017)

Metformin use and cardiovascular outcomes in patients with diabetes and chronic kidney disease: a nationwide cohort study
por: Kim, Min-Ho, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7ko97l4cp595d8alotsupfugrj